Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.
O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. O'Malley DM, et al. Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31. Future Oncol. 2024. PMID: 39082675 Free PMC article.
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA, Hancock LM, Wilken J, Weller J, Scott N, Gocke A, Lewin JB, Kaczmarek O, Mendoza JP, Golan D. Gudesblatt M, et al. Adv Ther. 2024 Aug;41(8):3059-3075. doi: 10.1007/s12325-024-02902-0. Epub 2024 Jun 11. Adv Ther. 2024. PMID: 38861218 Free PMC article.
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner FL, Voet H, Bareket-Samish A, Kedar I, Goldberg Y, Peretz-Yablonski T, Kadouri L. Yerushalmi R, et al. Breast Cancer Res Treat. 2024 Jul;206(1):67-76. doi: 10.1007/s10549-024-07271-4. Epub 2024 Apr 3. Breast Cancer Res Treat. 2024. PMID: 38568368 Free PMC article.
Shedding new light for nurses: Enhancing pressure injury prevention across skin tones with sub-epidermal moisture assessment technology.
Osborne Chambers C, Thompson JA. Osborne Chambers C, et al. J Adv Nurs. 2024 Jul;80(7):2801-2812. doi: 10.1111/jan.16040. Epub 2024 Jan 19. J Adv Nurs. 2024. PMID: 38243619
DESIGN: Quality improvement study employing Kurt Lewin's change model emphasizing planning, implementation, evaluation and sustainable change. ...CONCLUSION: Implementing SEM assessment technology enabled equitable PI care for all population types and resulte …
DESIGN: Quality improvement study employing Kurt Lewin's change model emphasizing planning, implementation, evaluation and sus …
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk; RECOVERY Collaborative Group. RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, et al. Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13. Lancet. 2023. PMID: 37060915 Free PMC article. Clinical Trial.
HIV residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men.
Aubé E, Lewin A, O'Brien SF, Grégoire Y, Pillonel J, Steele WR, Custer B, Davison KL, Germain M, Seed CR, Camirand Lemyre F; Surveillance, Risk Assessment and Policy Subgroup of the ISBT Transfusion Transmitted Infectious Diseases Working Party. Aubé E, et al. Vox Sang. 2022 Feb;117(2):201-207. doi: 10.1111/vox.13176. Epub 2021 Jul 15. Vox Sang. 2022. PMID: 34268781
The aim of this paper was to model the Canadian residual risk of HIV-positive source plasma incorporating pathogen inactivation (PI) under no MSM deferral scenarios for apheresis plasma donations. MATERIALS AND METHODS: A combined Bayesian network (BN) and Monte Carlo appr …
The aim of this paper was to model the Canadian residual risk of HIV-positive source plasma incorporating pathogen inactivation (PI) …
28 results